Malek, E., Kansagra, A., Costa, L., Usmani, S. Z., Vij, R., Kumar, S., … Liedtke, M. (2021). Triple-class refractory disease as a modern therapeutic benchmark for clinical trials testing new agents for relapsed refractory Multiple Myeloma. In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (Vol. 21, pp. S148–S149).

Malek, Ehsan, Ankit Kansagra, Luciano Costa, Saad Z. Usmani, Ravi Vij, Shaji Kumar, Kelly Godby, et al. “Triple-class refractory disease as a modern therapeutic benchmark for clinical trials testing new agents for relapsed refractory Multiple Myeloma.” In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 21:S148–49, 2021.

Malek E, Kansagra A, Costa L, Usmani SZ, Vij R, Kumar S, et al. Triple-class refractory disease as a modern therapeutic benchmark for clinical trials testing new agents for relapsed refractory Multiple Myeloma. In: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2021. p. S148–9.

Malek, Ehsan, et al. “Triple-class refractory disease as a modern therapeutic benchmark for clinical trials testing new agents for relapsed refractory Multiple Myeloma.” CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, vol. 21, 2021, pp. S148–49.

Malek E, Kansagra A, Costa L, Usmani SZ, Vij R, Kumar S, Godby K, Bal S, Cornell R, Kang Y, Umyarova E, Giri S, Chhabra S, Callander NS, Hari P, Liedtke M. Triple-class refractory disease as a modern therapeutic benchmark for clinical trials testing new agents for relapsed refractory Multiple Myeloma. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2021. p. S148–S149.